NL-OMON31158尚未招募4 期
A phase IV, long-term, open-label, multicenter extension study to evaluate the safety and tolerability of ranibizumab in subjects with subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) - SECURE
适应症
试验速览
- 阶段
- 4 期
- 状态
- 尚未招募
- 发起方
- ovartis
- 入组人数
- 18
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Signed informed consent
- •Completion of 12-month treatment period of study CRFB002A2302 (EXCITE) or CRFB002A2303 (SUSTAIN) study.
排除标准
- •Concurrent participation in another clinical trial, i.e. use of other investigational drugs at the time of enrollment.
研究者
相似试验
进行中（未招募）
不适用
A phase IV, long-term, open-label, multicenter extension study to evaluate the safety and tolerability of ranibizumab in subjects with subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) - SECUREStudy population will consist of patients with choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) who received treatment in either of the two ongoing ranibizumab studies RFB002A2302 (EXCITE) or RFB002A2303 (SUSTAIN). It is estimated that approximately 200 patients will be screened and assigned to treatment from approximately 40 centers in Europe.MedDRA version: 9.1Level: LLTClassification code 10060837Term: Choroidal neovascularizationEUCTR2007-000743-95-NLovartis Pharma200
进行中（未招募）
不适用
A phase IV, long-term, open-label, multicenter extension study to evaluate the safety and tolerability of ranibizumab in subjects with subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) - SECUREEUCTR2007-000743-95-BEovartis Pharma Services AG200
进行中（未招募）
不适用
A phase IV, long-term, open-label, multicenter extension study to evaluate the safety and tolerability of ranibizumab in subjects with subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) - SECUREStudy population will consist of patients with choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) who received treatment in either of the two ongoing ranibizumab studies RFB002A2302 (EXCITE) or RFB002A2303 (SUSTAIN). It is estimated that approximately 200 patients will be screened and assigned to treatment from approximately 40 centers in Europe.EUCTR2007-000743-95-HUovartis Pharma Services AG200
进行中（未招募）
不适用
A phase IV, long-term, open-label, multicenter extension study to evaluate the safety and tolerability of ranibizumab in subjects with subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) - SECUREStudy population will consist of patients with choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) who received treatment in either of the two ongoing ranibizumab studies RFB002A2302 (EXCITE) or RFB002A2303 (SUSTAIN). It is estimated that approximately 200 patients will be screened and assigned to treatment from approximately 40 centers in Europe.EUCTR2007-000743-95-PTovartis Pharma Services AG200
进行中（未招募）
1 期
A phase IV, long-term, open-label, multicenter extension study to evaluate the safety and tolerability of ranibizumab in subjects with subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) - SECUREStudy population will consist of patients with choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) who received treatment in either of the two ongoing ranibizumab studies RFB002A2302 (EXCITE) or RFB002A2303 (SUSTAIN). It is estimated that approximately 200 patients will be screened and assigned to treatment from approximately 40 centers in Europe.EUCTR2007-000743-95-GBovartis Pharma Services AG